Patent ID: 11963959
Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treatment of COVID-19 caused by SARS-COV-1, SARS-CoV-2 (Covid-19) and MERS-CoV, and variants within each, in a mammalian subject in need therefore, comprising administering to the subject an effective amount of a pyrroloquinazoline of the following formulae:, , wherein
X1 and X2 are CH and joined together by a double bond;
Y is independently C;
Z is CH2;
R1 is 2-trifluorophenyl, 2-methylphenyl, 4-nitrophenyl, ethylene, 2-fluorophenyl, pyridine-3-yl, pyridine-2-yl, pyridine-4-yl or cyclohexyl;
R2 is H or methyl;
R3 is H;
R4 and R5 are independently amino groups;
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.